课题基金 / 基金详情

Multidisciplinary research for molecular mechanism of cancer progression and development of diagnostic and therapeutic tool

Multidisciplinary research for molecular mechanism of cancer progression and development of diagnostic and therapeutic tool
癌症进展分子机制的多学科研究及诊断和治疗工具的开发
批准号:
18209043
负责人:
ARII Shigeki
金额:
$32.03万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

ARII Shigeki的其他基金

相似基金

相关文献

中文摘要
翻译
这个研究项目产生了以下结果。1)肝细胞癌(HCC)侵袭性复发的预测因素及新分子靶点的发现:发现HCC患者的预后与复发方式有关,预后指标为肿瘤分化、肿瘤大小和在基因组不稳定性中起关键作用的极光激酶B (aurora kinase B, ARKB)。ARKB被认为是HCC治疗的一个有前景的分子靶点。2)临床意义的差距交界细胞间通信,Conexin (Cg) 43:3)残雪43发现促进肝癌的生长,和可能的分子的目标,同时维生素K 2被发现抑制肝癌的生长通过upregulation Cx32 Cx43.4)的差别,对这些基因的识别肝细胞癌的致癌作用和发展:我们确定CREB3L4 INTS3, SNAPAP位于1 q 21.5)识别胰腺癌转移的基因:我们发现Gr7被FAK磷酸化,从而诱导细胞侵袭。我们合成了抑制Grb7磷酸化的肽G7-18NATE-P,从而阐明了其对胰腺癌腹膜播散模型的抑制作用。6) IKKB激酶(Iκ B kinase, IKKB)抑制胰腺癌的作用:在异种移植模型中发现IKKB抑制剂SiRNA和合成化合物IMD-0354抑制胰腺癌的生长。
英文摘要
This research project yielded the following results.1) Predictive factors for aggressive recurrence of hepatocellular carcinoma (HCC) and identification of a novel molecular target: A prognosis of HCC patients was found to depend on the mode of recurrence, and prognostic indicators were tumor differentiation, tumor size, and aurora kinase B (ARKB) which plays a key role in genome instability. ARKB is considered to be a promising molecular target for HCC treatment.2) Clinical implication of Gap junctional intercellular communication, Conexin (Cg) 43:3) Cx 43 was found to facilitate the growth of HCC, and to be a possible molecular target, and also Vitamin K 2 was found to suppress HCC growth through upregulation of Cx32 and downregulation of Cx43.4) Identification of genes responsible for carcinogenesis and development of HCC : We identified CREB3L4, INTS3, SNAPAP located at 1q 21.5) Identification of genes responsible for pancreatic cancer metastasis : We identified Gr7 which is phospholylated with FAK, thereby inducing cell invasion. We synthesized a peptide, G7-18NATE-P which inhibits phospholylation of Grb7, thereby clarifying the inhibitory effect on the peritoneal dissemination model of pancreas cancer.6) Effect of Iκ B kinase (IKKB) inhibition on pancreas cancer: SiRNA and synthesized compound, IMD-0354 for IKKB inhibitor were found to suppress the growth of pancreas cancer in the xenograft model.
期刊论文(79)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.canlet.2007.12.019
发表时间: 2008-05-08
期刊: CANCER LETTERS
影响因子: 9.7
作者: [Kaneda, Makoto, Zhang, Dan, Morita, Ikuo]
通讯作者: Morita, Ikuo
BAMCA (BAC-arraybased MCA)法による肝癌DNAメチル化遺伝子の網羅的控索
利用BAMCA(BAC-arraybased MCA)方法全面寻找肝癌DNA甲基化基因
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [趙 晨, 井本逸勢, 井上 純田中真二, 有井滋樹, 田中 博, 稲澤譲治.]
通讯作者: 稲澤譲治.
DOI: --
发表时间: 2006
期刊:
影响因子: --
作者: [中島知明, 安居幸一郎, 稲垣恭和, 全圭夏, 伊藤義人, 谷脇雅史, 有井滋樹, 岡上 武.]
通讯作者: 岡上 武.
DOI: --
发表时间: 2006
期刊:
影响因子: --
作者: [S. Tanaka, T. Ochiai, M. Yasen, A. Kudo, N. Nakamura, K. Ito, K. Teramoto, S. Arii.]
通讯作者: S. Arii.
65
    Study on the molecular diagnosis of metastasis and recurrence and molecular targeted therapy for intractable hepato-pancreatic cancer
    • 批准号:
      20249061
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $30.87万
    • 财政年份:
      2008
    • 负责人:
      ARII Shigeki
    • 依托单位:
    Development of molecular- targeting therapy and prediction of mode of recurrence by analysis of molecular mechanism of invasion and metastasis of hepatocellular carcinoma
    • 批准号:
      16390375
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.15万
    • 财政年份:
      2004
    • 负责人:
      ARII Shigeki
    • 依托单位:
    Order-made medicine for cancer in the viewpoint of angiogenesis
    • 批准号:
      14370379
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.34万
    • 财政年份:
      2002
    • 负责人:
      ARII Shigeki
    • 依托单位:
    Study on the improvement of liver injury by controlling sinusoidal cells and spleen
    海外基金